<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690274</url>
  </required_header>
  <id_info>
    <org_study_id>BF2.649</org_study_id>
    <nct_id>NCT00690274</nct_id>
  </id_info>
  <brief_title>Study to Demonstrate Cognitive Enhancing Effects of BF2.649</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Study to Demonstrate the Cognitive Enhancing Effects of BF2.649 in People With Schizophrenia and Schizoaffective Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bioprojet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the cognitive enhancing effect of BF2.649 and to evaluate the effect of BF2.649
      on symptom severity in persons with schizophrenia or schizoaffective disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will recruit persons with schizophrenia or schizoaffective disorder who are not currently
      experiencing an acute exacerbation of psychotic symptoms, but still display cognitive
      symptoms and have consequent psychosocial dysfunction. The subjects recruited will be taking
      haloperidol, aripiprazole, risperidone or paliperidone. Each study subject will spend 4 weeks
      on a fixed dose of his or her APD with stable symptoms, during which time the baseline workup
      will be completed. At baseline (Week 0), each study subject will have a full symptom
      evaluation, side effects, and neuropsychological battery along with the full clinical
      laboratory and baseline safety study workup. Next, subjects, while remaining on their APD,
      will be randomized to BF2.649 or placebo. The dose of BF2.649 will be up to 20 mg/day.
      Assessment of safety parameters (vital signs, EKGs, clinical labs) and side effects (adverse
      events, BAS, SAS) will occur once weekly for the first 4 weeks (through study week 4) and
      then every other week for the next 4 weeks (to study week 8) including End of Study (week
      12). An EEG will be taken at Week 1 and then at Week 8. Symptomatic outcome measures (PANSS
      and CGI) will be measured every two weeks during the double blind phase and at end of study.
      The neuropsychological battery will be done first at baseline and repeated at the end of the
      8-week double blind phase. After 8 weeks of medication, the double-blinded drug will be
      stopped and the patient followed for a period 4 weeks with clinical and side effect measures
      recorded weekly with the exception of clinical laboratories, which will be recorded every
      other week. Each study participant will be seen weekly throughout the protocol for clinical
      assessment.

      Finally, persons with schizophrenia display severe deficits in neuropsychological, cognitive,
      and social functioning. Our primary outcome measure will be to determine if BF2.649 can
      produce a cognitive enhancing effect and repair some of the neuropsychological deficiencies
      seen in this population. Therefore, blood samples will be collected from study volunteers for
      DNA analysis, serology testing, and white cell immortalization during and only at the
      baseline phase of the study (Week 0). If a therapeutic effect is seen, it will be important
      to be able to identify the genetic characteristics of the responders to BF2.649.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Delayed Recall From Baseline to 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Brief Visuospatial Memory Test-Revised (Delayed Recall) is a neuropsychological test to assess one's ability to recall a previously exposed stimuli. The t-score range (as being reported) is from 35-81, with higher scores being better and indicating being able to recall more items after a 45-minute delay. (The t-score is a score calculated from the individual score and based on each individual's age group.) The t-scores are then grouped together and reported as a mean with the standard deviation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Effect of BF2.649 on Symptom Severity Between Baseline and Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Montgomery-Asberg Depression Rating Scale (MADRS), a depression rating scale. The score can total from 0-60, with the higher score indicating more severe depressive symptoms. The scores indicate a change between baseline and 12 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Volunteers are given Placebo, up to 20mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BF2.649</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteers are given BF2.649, up to 20mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BF2.649</intervention_name>
    <description>up to 20mg per day</description>
    <arm_group_label>BF2.649</arm_group_label>
    <other_name>Study medication</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>up to 20mg per day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>cornstarch capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV diagnosis of schizophrenia and schizoaffective disorder and not experiencing an
             acute exacerbation of severe psychosis

          -  Stable antipsychotic drug treatment for at least 4 weeks of Abilify or Haldol or
             willing to switch to either of these two APDs.

          -  Able to execute written informed consent.

          -  Males and females, between the ages of 18-55 years old, in good health (based on
             medical history, physical examination, electrocardiograms, and clinical laboratory
             tests)

          -  All races and ethnicities fluent and literate in English.

        Exclusion Criteria:

          -  Diagnosis of DSM-IV alcohol or substance abuse within the last month or DSM-IV alcohol
             or substance dependence within the last 3 months.

          -  Patients on a stable regimen of antipsychotic medication (other than Haldol or
             Abilify) for a minimum of 3 months who are not experiencing psychotic symptoms.

          -  Clinically significant abnormal pre-admission vital signs, EKGs, or clinical
             laboratory evaluations, in which the principle investigator deems the
             subject-volunteer ineligible for the study.

          -  Any patient scheduled to undergo any surgical procedure during the duration of the
             study

          -  Patients suffering an acute psychotic episode within the previous 30 days as
             determined by the attending physician or Principal Investigator.

          -  Patients on any antihistaminergic antipsychotic medications who are not willing to
             switch to either Haldol or Abilify.

          -  Any patient who has received any known hepatic or renal clearance altering agents
             (e.g., erythromycin, cimetidine, barbiturates, phenothiazines, etc.) for a period of 3
             months before the first dose of study medication

          -  Patients taking any concurrent medications for a major medical illness.

          -  Any patients who test positive for HIV.

          -  Any patient testing positive for Hepatitis B or C whose liver panel (taken during
             clinical laboratories) reports clinically significant abnormalities of liver enzyme
             ranges suggesting a cirrhotic stage.

          -  Any patient who has donated plasma or blood within 30 days before the first dose of
             study medication

          -  Concurrent treatment with electroconvulsive therapy.

          -  Pregnant women, women in the child bearing age without an efficacious contraceptive
             device, or women who are breast feeding.

          -  Mental capacity is limited to the extent that the patient cannot provide legal consent
             or understand information regarding the side effects or tolerance of the study drug

          -  Any patient judged by the principal investigator to be inappropriate for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol A Tamminga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 2, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <results_first_submitted>October 16, 2018</results_first_submitted>
  <results_first_submitted_qc>March 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2019</results_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>cognitive deficients</keyword>
  <keyword>cognitive enhancing</keyword>
  <keyword>antipsychotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Volunteers are given Placebo, up to 20mg per day
Placebo: up to 20mg per day</description>
        </group>
        <group group_id="P2">
          <title>BF2.649</title>
          <description>Volunteers are given BF2.649, up to 20mg per day
BF2.649: up to 20mg per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Volunteers are given Placebo, up to 20mg per day
Placebo: up to 20mg per day</description>
        </group>
        <group group_id="B2">
          <title>BF2.649</title>
          <description>Volunteers are given BF2.649, up to 20mg per day
BF2.649: up to 20mg per day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Delayed Recall From Baseline to 12 Weeks</title>
        <description>The Brief Visuospatial Memory Test-Revised (Delayed Recall) is a neuropsychological test to assess one's ability to recall a previously exposed stimuli. The t-score range (as being reported) is from 35-81, with higher scores being better and indicating being able to recall more items after a 45-minute delay. (The t-score is a score calculated from the individual score and based on each individual's age group.) The t-scores are then grouped together and reported as a mean with the standard deviation.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Volunteers are given Placebo, up to 20mg per day
Placebo: up to 20mg per day</description>
          </group>
          <group group_id="O2">
            <title>BF2.649</title>
            <description>Volunteers are given BF2.649, up to 20mg per day
BF2.649: up to 20mg per day</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Delayed Recall From Baseline to 12 Weeks</title>
          <description>The Brief Visuospatial Memory Test-Revised (Delayed Recall) is a neuropsychological test to assess one's ability to recall a previously exposed stimuli. The t-score range (as being reported) is from 35-81, with higher scores being better and indicating being able to recall more items after a 45-minute delay. (The t-score is a score calculated from the individual score and based on each individual's age group.) The t-scores are then grouped together and reported as a mean with the standard deviation.</description>
          <units>t-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2" spread="2.9"/>
                    <measurement group_id="O2" value="43.4" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Effect of BF2.649 on Symptom Severity Between Baseline and Week 12</title>
        <description>Montgomery-Asberg Depression Rating Scale (MADRS), a depression rating scale. The score can total from 0-60, with the higher score indicating more severe depressive symptoms. The scores indicate a change between baseline and 12 weeks.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Volunteers are given Placebo, up to 20mg per day
Placebo: up to 20mg per day</description>
          </group>
          <group group_id="O2">
            <title>BF2.649</title>
            <description>Volunteers are given BF2.649, up to 20mg per day
BF2.649: up to 20mg per day</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Effect of BF2.649 on Symptom Severity Between Baseline and Week 12</title>
          <description>Montgomery-Asberg Depression Rating Scale (MADRS), a depression rating scale. The score can total from 0-60, with the higher score indicating more severe depressive symptoms. The scores indicate a change between baseline and 12 weeks.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.5"/>
                    <measurement group_id="O2" value="-4.9" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Volunteers are given Placebo, up to 20mg per day
Placebo: up to 20mg per day</description>
        </group>
        <group group_id="E2">
          <title>BF2.649</title>
          <description>Volunteers are given BF2.649, up to 20mg per day
BF2.649: up to 20mg per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>suicidality</sub_title>
                <description>Participant was expressing suicidal ideation and was psychiatrically hospitalized for evaluation.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carol A. Tamminga, MD</name_or_title>
      <organization>University of Texas Southwestern Medical Center</organization>
      <phone>214-645-2789</phone>
      <email>carol.tamminga@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

